TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $288,340 | -99.7% | 32,235 | -99.5% | 0.00% | -100.0% |
| Q2 2023 | $107,008,104 | -30.5% | 6,966,970 | +1.8% | 0.07% | -34.3% |
| Q1 2023 | $153,957,879 | +43.8% | 6,845,813 | +34.5% | 0.10% | +34.2% |
| Q4 2022 | $107,061,749 | +10.9% | 5,091,285 | -34.9% | 0.08% | +5.6% |
| Q3 2022 | $96,497,401 | -1.4% | 7,824,970 | +93.8% | 0.07% | +7.5% |
| Q2 2022 | $97,871,000 | -8.5% | 4,038,631 | -2.7% | 0.07% | +28.8% |
| Q1 2022 | $107,003,000 | -14.2% | 4,152,047 | +3.4% | 0.05% | 0.0% |
| Q4 2021 | $124,675,000 | +27.8% | 4,016,158 | -0.2% | 0.05% | +20.9% |
| Q3 2021 | $97,561,000 | +71.2% | 4,023,074 | +3.0% | 0.04% | +79.2% |
| Q2 2021 | $56,977,000 | -45.0% | 3,905,113 | -5.9% | 0.02% | -48.9% |
| Q1 2021 | $103,639,000 | -6.9% | 4,150,556 | +1.6% | 0.05% | -9.6% |
| Q4 2020 | $111,297,000 | – | 4,083,553 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |